We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Board of Directors of Barr Pharmaceuticals, Inc. approved a change in the company's fiscal year from June 30 to December 31, effective immediately.
Drug companies have come under scrutiny recently for recruiting former cheerleaders to fill sales jobs and lavishing doctors with "seminars" at exotic resorts.
Millennium Pharmaceuticals has outbid Genzyme Corp. to acquire AnorMed, offering $515 million for the biotech firm. Early Tuesday, Millennium said it intends to buy Vancouver-based AnorMed for $12 a share, or a 21% premium over AnorMed's Monday closing price.
Genentech Inc. has added warnings about a rare brain condition called reversible posterior leukoencephalopathy syndrome, or RPLS, in patients using its cancer drug Avastin, the Food and Drug Administration said.
The FDA announced Sept. 18 it has approved Schering-Plough's drug Noxafil, which prevents invasive fungal infections in people with weakened immune systems.
The long-running game of escalating bids for control of Croatian generic drugmaker Pliva appears to be over as Actavis has folded its hand and left Barr Pharmaceuticals as the only player at the table.
The Institute of Medicine (IOM) study on the FDA's drug safety practices could do long-term damage to the industry bottom line and will likely spur legislation in the next Congress, sources say.
SCOLR Pharma, Inc. announced that it has entered into a research collaboration with a US-based biopharmaceutical company to develop an oral formulation of a promising antiviral compound using SCOLR's proprietary CDT drug delivery platform.